Chinese medical devices maker, Mindray Medical International Ltd ( MR - Analyst Report ) , recently announced that it will present its products at the American Association for Clinical Chemistry’s 2012 Clinical Lab Expo. The exhibition will be held at Los Angeles, California, from July 17 to July 19.

The sophisticated and high-profile domain of the Clinical Lab Expo attracts reputed clinical laboratory professionals. Mindray is enthused about the opportunity to participate in the conference. It will use the opportunity to display its complete range of in-vitro diagnostic products as well as new products such as BS-2000 Auto Biochemistry Analyzer and EH-2050B Plus Automatic Urine Sediment Analyzer.

The BS-2000 modular system is the company’s fastest biochemistry analyzer. The output range is 2,000 photometric tests for single modules, to 4,400 for dual modules with electrolyte tests. Given its high speed and methodological traceability, the product will be beneficial for hospital and clinical laboratories with high sample volumes, adding to versatility.

Mindray believes that BS-2000 has a high level of efficiency, automation and scalability. It also boasts of the easy consolidation of the product with its future offerings.

The Automatic Urine Sediment Analyzer EH-2050B for comprehensive urinalysis of patients is for automatic detection of the presence of red blood cells and other elements in the patients’ urine samples. Additionally, EH-2050B can be used in conjunction with various urinary dry-chemistry analyzers. The subsequent data from such analysis can help in developing an integrated urinalysis report of the patient.

Mindray is a bellwether in the Chinese MedTech industry with a solid international presence. A key distinction with domestic competitors is that the majority of Mindray’s products have CE Mark and/or Food and Drug Administration (FDA) clearance.

Mindray remains committed to innovative and high-quality product development in order to deliver high-performance towards consumer demand. The company maintains a decent product pipeline and brings out several new products each year. New products contribute in a major way to Mindray’s revenues.

The company has entered the premium segment globally, where its competitive advantage is still unclear. Also, on the negative side, health care reforms in China and the U.S. may reduce demand for Mindray’s products. Competition is fierce and could lead to price erosion over time.

Mindray’s competitors in different niche segments include GE Healthcare, a part of General Electric ( GE - Analyst Report ) , Phillips Healthcare under Philips ( PHG - Analyst Report ) and Siemens ( SI - Analyst Report ) . Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).